IP Library Granted Patent US 9,255,259
Granted Patent B2
US 9,255,259 · App. 12/931,760 · Granted Feb 9, 2016

Targeted genomic modification with partially single-stranded donor molecules

Inventors: Gregory J. Cost (Berkeley, CA); Dmitry M. Guschin (Albany, CA); Fyodor Urnov (Richmond, CA)
Assignee: Sangamo BioSciences, Inc.
C12N9/22C12N15/907C07K2319/80C07K2319/81
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,255,259
App. No.
12/931,760
Granted
Feb 9, 2016
Kind
B2
Abstract

Disclosed herein are donor molecules comprising single-stranded complementary regions flanking one or more sequences of interest. The donor molecules and/or compositions comprising these molecules can be used in methods for targeted integration of an exogenous sequence into a specified region of interest in the genome of a cell.

Claims (15)

1. A mammalian or plant cell comprising:

a genome comprising a target site of interest;

a non-naturally occurring zinc finger nuclease that is capable of generating a double-stranded break with single-stranded overhangs in the genome at the target site of interest; and

an exogenous linear donor nucleic acid molecule comprising a double-stranded exogenous sequence of interest having first and second ends and first and second single-stranded sequences of 4 to 10 nucleotides at the first and second ends of the double-stranded sequence,

wherein the first and second single-stranded sequences are 100% complementary to the single-stranded overhangs in the genome at the target site of interest such that the exogenous linear donor sequence is capable of being directly integrated at the target site of interest by annealing of the complementary first and second single-stranded sequences and non-homologous end joining (NHEJ)-mediated targeted integration.

2. The cell of claim 1 , wherein the exogenous linear donor further comprises one or more phosphorothioate phosphodiester bonds between one or more nucleic acids.

3. The cell of claim 1 , wherein one or more nucleic acids of the exogenous linear donor are methylated or comprise non-natural nucleotide analogs.

4. The cell of claim 1 , wherein the sequence of interest comprises a polynucleotide encoding a functional polypeptide.

5. The cell of claim 4 , wherein the polypeptide is selected from the group consisting of an antibody, an antigen, an enzyme, a growth factor, a receptor, a hormone, a lymphokine, a cytokine, and a reporter.

6. The cell of claim 1 , wherein the sequence of interest comprises a sequence encoding a functional RNA.

7. The cell of claim 1 , wherein the sequence of interest comprises an integration site.

8. A method of integrating a linear nucleic acid molecule in to the genome of a cell, the method comprising:

providing the cell according to claim 1 ; and

creating a double-stranded break in the genome of the cell using a zinc finger nuclease such that the linear nucleic acid molecule is integrated at the site of the double-stranded break.

9. The method of claim 8 , wherein the nuclease comprises a naturally occurring or non-naturally occurring cleavage domain from a Type IIS restriction endonuclease.

Assignments (2)
CHANGE OF NAME Recorded Feb 14, 2018
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 045338/0889 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2011
From: COST, GREGORY J.; GUSCHIN, DMITRY; URNOV, FYODOR
To: SANGAMO BIOSCIENCES, INC.
Reel/Frame 026215/0565 →
Continuity (3)
Provisional Application 61337756 · Feb 9, 2010
Provisional Application 61342934 · Apr 21, 2010
Related Publication 20110207221A1 · Aug 25, 2011